Introduction: Severe hypertriglyceridemia (sHTG) is a complex disorder of lipid metabolism characterized by plasma levels of triglyceride (TG) greater than 885 mg/dl (>10 mmol/L). The treatment of sHTG syndromes is challenging because conventional treatments are often ineffective in reducing TG under the threshold to prevent acute pancreatitis (AP). The inhibition of APOC3, which encodes a protein involved in triglyceride (TG)-rich lipoproteins (TGRLs) removal, has been reported to be a novel target for the treatment of sHTG. Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment. Areas covered: This review summarizes the evidences on the efficacy and safety of volanesorsen for the treatment of sHTG syndromes. Expert opinion: Volanesorsen effectively reduces TG in sHTG through a mechanism that is mainly LPL-independent, potentially decreasing the risk of AP. Some safety concerns have been raised with the use of volanesorsen, mainly represented by the occurrence of thrombocytopenia. Due to the potential severity of side effects, some caution is needed before affirming the long-term utility of this drug. Despite this, volanesorsen currently remains the only drug that has been demonstrated effective in FCS, which otherwise remains an untreatable disease.

Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia / D'Erasmo, L.; Gallo, A.; Di Costanzo, A.; Bruckert, E.; Arca, M.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 21:14(2020), pp. 1-10. [10.1080/14656566.2020.1787380]

Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia

D'Erasmo L.;Di Costanzo A.;Arca M.
2020

Abstract

Introduction: Severe hypertriglyceridemia (sHTG) is a complex disorder of lipid metabolism characterized by plasma levels of triglyceride (TG) greater than 885 mg/dl (>10 mmol/L). The treatment of sHTG syndromes is challenging because conventional treatments are often ineffective in reducing TG under the threshold to prevent acute pancreatitis (AP). The inhibition of APOC3, which encodes a protein involved in triglyceride (TG)-rich lipoproteins (TGRLs) removal, has been reported to be a novel target for the treatment of sHTG. Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment. Areas covered: This review summarizes the evidences on the efficacy and safety of volanesorsen for the treatment of sHTG syndromes. Expert opinion: Volanesorsen effectively reduces TG in sHTG through a mechanism that is mainly LPL-independent, potentially decreasing the risk of AP. Some safety concerns have been raised with the use of volanesorsen, mainly represented by the occurrence of thrombocytopenia. Due to the potential severity of side effects, some caution is needed before affirming the long-term utility of this drug. Despite this, volanesorsen currently remains the only drug that has been demonstrated effective in FCS, which otherwise remains an untreatable disease.
2020
antisense oligonucleotides; Apo c-III; clinical trials; familial chylomicronemia syndrome; orphan drug; severe hypertriglyceridemia; treatment; volanesorsen; Apolipoprotein C-III; Europe; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Lipoproteins; Oligonucleotides; Oligonucleotides, Antisense; Pancreatitis; Thrombocytopenia; Triglycerides
01 Pubblicazione su rivista::01a Articolo in rivista
Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia / D'Erasmo, L.; Gallo, A.; Di Costanzo, A.; Bruckert, E.; Arca, M.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 21:14(2020), pp. 1-10. [10.1080/14656566.2020.1787380]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1497876
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact